7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
The European Union must improve its biosimilar medicines policy to increase equity of access and bring much needed savings to healthcare budgets, says Medicines for Europe, the trade group that represents makers of generic and biosimilar medicines in the region. 25 May 2023
Prime Minister Fumio Kishida has announced the government of Japan's pledge to contribute $200 million to the Global Health Innovative Technology Fund (GHIT Fund). 25 May 2023
USA-based ClearPoint Neuro a global therapy-enabling platform company providing navigation and delivery to the brain, saw its shares rise 3% to $8.15 pre-market today, on news of a multi-year license agreement with Belgium’s largest pharma company, UCB, to partner on drug delivery platforms for UCB’s gene therapy portfolio. 25 May 2023
Shares of US oncology drugmaker Mirati Therapeutics closed down 4% on Wednesday and were a further 8.7% lower at $40.01 in pre-market activity today, after it revealed that the SAPPHIRE study did not meet its primary endpoint of overall survival (OS) at the final analysis. 25 May 2023
The leading trade body for the British pharmaceutical industry has appointed a new president, current Pfizer UK managing director Susan Rienow. 25 May 2023
German generics major STADA Arzneimittel today revealed that, following a six-day inspection, the US Food and Drug Administration (FDA) has approved the STADA-controlled entity as a manufacturing and storage site for Retacrit (epoetin alfa-epbx) drug substance, at the Norbitec biologics facility in Uetersen, Germany. 25 May 2023
A new proposal from the US Department of Health and Human Services (HHS) is proposing steps to further drive down prescription drug costs in Medicaid, building on the Biden administration’s widespread efforts to lower medicine prices. 24 May 2023
Boston, USA-based cell and gene therapy incubator ElevateBio has raised $401 million in a series D financing round led by AyurMaya Capital Management Fund. 24 May 2023
UK headquartered Biodexa Pharmaceuticals, a company developing treatments for metastatic brain cancers, has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, a private US precision oncology company developing novel therapeutics for the treatment of cancer. 24 May 2023
As part of its growth strategy, UK biotech Fixed Phage, a developer of proprietary, anti-infective technologies, today announced the appointment Dr Neil Clelland as its new chief executive (CEO). 24 May 2023
Adding to previous collaborations between the companies, Icelandic biosimilars company Alvotech and privately-held UK firm Advanz Pharma have entered into an exclusive partnership agreement regarding the supply and commercialization of five biosimilar candidates in Europe. 24 May 2023
Shares of Belgian biotech BioSenic were up more than 11% at 0.13 euros today, after it announced the signing of a term sheet with Pluristyx, a leading provider of gene-edited iPSC and cell therapy solutions, with a view to further negotiate the terms and conditions of a potential license and collaboration agreement. 24 May 2023
Following a positive advisory committee vote last month, the US Food and Drug Administration (FDA) yesterday approved Xacduro (sulbactam for injection; durlobactam for injection), developed by Entasis Therapeutics, a subsidiary of Innoviva. 24 May 2023
US RNA medicines company Wave Life Sciences saw its shares close up 2.7% at $3.81 yesterday, despite announcing that it is discontinuing an important program. 24 May 2023
Industry analyst GlobalData has outlined what it sees as a significant market opportunity for new entrants targeting Parkinson’s disease (PD). 24 May 2023
While financial experts may debate the merits and demerits of the initial public offering (IPO), it’s not the only way to take a company public. 24 May 2023
Ichthyosis is a heterogenous group of disorders characterized by dry, itchy skin that appears scaly and rough like fish scales.1,2 The first case of ichthyosis was described 24 May 2023
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024